



*Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer's Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in-development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models.*

## Panax ginseng

### Evidence Summary

Some studies have shown that ginseng improves cognitive functions and decreases mortality and cancer risk in humans; safe when taken alone, but some drug interactions are known.

**Neuroprotective Benefit:** Numerous studies have reported cognitive benefit with ginseng in healthy people as well as in dementia patients, but the evidence remains inconclusive due to the lack of large, long-term well-designed trials.

**Aging and related health concerns:** Ginseng intake is associated with lower risks for mortality and cancers; also, some benefits seen in Asian people with ischemic heart disease, diabetes, hypertension, hypercholesteremia, and fatigue.

**Safety:** Numerous meta-analyses have reported that ginseng is generally safe when taken alone; however, ginseng interacts with several medications.

<b>Availability:</b> OTC. No pharmaceutical grade product.	<b>Dose:</b> 200-400 mg/day for cognitive benefit; higher doses for other indications	<b>Chemical formula:</b> e.g., $C_{42}H_{72}O_{14}$ (Ginsenoside Rg1); $C_{54}H_{92}O_{23}$ (Ginsenoside Rb1)
<b>Half life:</b> 0.2-18 hr depending on the ginsenoside	<b>BBB:</b> some ginsenosides are penetrant	<b>MW:</b> e.g., 801.1 (Ginsenoside Rg1); 1109.3 (Ginsenoside Rb1)
<b>Clinical trials:</b> the largest meta-analysis included a total of 1,549 patients with ischemic heart disease across 18 RCTs	<b>Observational studies:</b> the largest cohort study included 6,282 Korean subjects, of whom 3,680 subjects had used ginseng	

**What is it?** Ginseng (typically the root) is extensively used in traditional Chinese medicine to promote longevity, cognitive enhancement, and rejuvenation from stress, weakness, and fatigue, as well as treating illnesses including diabetes, cardiovascular disease, and inflammatory disorders [1]. Ginseng typically refers to plants of the genus *Panax*, which includes at least 11 species. The species most commonly used and studied in herbal medicine is *Panax ginseng*, also referred to as Korean or Asian ginseng. Many other species of *Panax* genus are also widely available, including *Panax quinquefolius* (American ginseng), *Panax japonicus* (Japanese ginseng), and *Panax notoginseng* (pseudoginseng).

Ginsenosides, which are triterpene saponins, are considered the main active compounds that contribute to the purported cognitive effects of ginseng [1]. There are well over 100 ginsenosides. Ginseng and ginsenosides have been reported to have anti-oxidative, anti-inflammatory, anti-neoplastic, and immunomodulatory effects [2].

**Neuroprotective Benefit:** Numerous studies have reported cognitive benefit with ginseng in healthy people as well as in dementia patients, but the evidence remains inconclusive due to the lack of large, long-term well-designed trials.

*Types of evidence:*

- 4 meta-analyses
- 13 clinical trials
- 2 observational studies



- Numerous laboratory studies

Human research to suggest prevention of dementia, prevention of decline, or improved cognitive function?

There have been numerous clinical trials and observational studies on ginseng supplementation. While some studies have shown benefit (described below), others have shown lack of benefit [3; 4; 5; 6; 7]. Currently, there is a lack of conclusive evidence to show a cognitive enhancing effect of *Panax ginseng* in healthy people.

A 2010 Cochrane meta-analysis of 9 double-blind randomized controlled trials in healthy subjects and in those with cognitive impairment reported that ginseng treatment (*Panax genus* extract or ginseng compound HT008-1) for 8-12 weeks suggested improvement in some aspects of cognitive function, behavior, and quality of life [8]. Pooling the data was impossible due to heterogeneity in outcome measures, trial duration, and ginseng dosage. Individual studies within the meta-analysis have shown that ginseng (200 mg/day) treatment significantly improved working memory after 8 weeks and mental arithmetic after 12 weeks [9], while no benefits were seen for attention or concentration. However, in a different study, ginseng treatment (400 mg/day) for 2 days significantly improved speed of attention compared to placebo, while no benefits were seen in quality of memory, speed of memory, working memory, or secondary memory [10]. In an older study, ginseng (400 mg/day) for 8-9 weeks improved selective reminding but did not improve attention, concentration, or psychomotor performance compared to placebo [11].

In a double-blind randomized controlled trial of 30 healthy young adults, a single dose of *Panax ginseng* (G115, 200 mg) significantly improved Serial Sevens subtraction task performance and significantly reduced subjective mental fatigue [12]. This benefit was not observed when a higher dose (400 mg) was ingested. Overall these data suggest that *Panax ginseng* can improve performance and subjective feelings of mental fatigue during sustained mental activity.

A review of 8 double-blind placebo-controlled studies in healthy subjects compared the cognitive effect sizes for *Panax ginseng*, *Bacopa monnieri*, and modafinil [13]. *Panax ginseng* studies used the standardized extract G115, which contains 4% ginsenosides. Seven of these studies were acute and one of the studies had a duration of 8 days. The highest effect sizes for cognitive outcomes were 0.77 for modafinil (visuospatial memory accuracy), 0.86 for ginseng (simple reaction time), and 0.95 for Bacopa



(delayed word recall). Interestingly another measure, reaction time on the 3-back working memory task, showed a large positive effect size ( $d = 0.806$ ) following acute ginseng administration and also had the largest impairment ( $d = -0.481$ ) following dosing for 8 days. It is unclear why acute versus chronic ginseng treatment had opposing effects. Authors speculated that ginseng may improve cognitive functions by glucoregulation, modulation of acetylcholine and dopamine activity as well as increasing nitric oxide synthesis [13].

In a prospective cohort study of 6,422 community-dwelling elderly (from the Korean Longitudinal Study on Cognitive Aging and Dementia), those who had higher lifetime cumulative ginseng intake (over 5 years) showed higher cognitive scores (measured by CERAD total scores--Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet neuropsychological battery) compared to the no-use group after controlling for age, sex, education, socioeconomic status, smoking, alcohol intake, cardiovascular disease, and APOE genotype [14]. However, changes in cognitive function over 4 years of follow-up did not differ based on ginseng intake. Percentage of cognitive impairment (MCI or dementia) was significantly lower in the high-use group (24.7%) compared to the low-use group (27.1%), and both groups had lower incidence of cognitive impairment compared to the no-use group (32.6%). However, after controlling for potential covariates, low-use or high-use of ginseng intake was not associated with lower incidence of cognitive impairment. While this study suggests that cumulative ginseng use for longer than 5 years may be beneficial to cognitive function, there may be many confounding factors.

*Human research to suggest benefits to patients with dementia:*

In a 2016 meta-analysis of 4 randomized controlled trials in Alzheimer's patients, the effectiveness of ginseng combined with conventional treatment was inconsistent as measured by MMSE, ADAS-cog, ADAS-noncog, and CDR [15]. This meta-analysis, the full text of which was not accessible, reported that benefits of ginseng on Alzheimer's patients were still inconclusive. The main limitations of the available studies were small sample sizes, poor methodological qualities and no placebo controls. Larger, well-designed studies are needed to test the effect of ginseng in Alzheimer's patients.

In contrast, an older 2009 systematic review of 2 randomized controlled trials in Alzheimer's patients suggested significant effect in favor of ginseng on the Mini-Mental Status Examination (weighted mean difference (WMD), 1.85; 95% CI, 0.88-2.82) and on the ADAS-cog (WMD, 3.09; 95% CI, 1.08-5.09) [16]. Details of the 2 trials are described below.

The first trial included 97 Alzheimer's patients; *Panax ginseng* treatment (powder, 4.5 g/day) for 12 weeks significantly improved cognitive scores as measured by ADAS-Cog and MMSE [17]. However, after discontinuing ginseng for 12 additional weeks, the improved ADAS and MMSE scores declined to scores comparable to the control group. Although these results suggest that *Panax ginseng* is clinically effective in improving cognitive functions in Alzheimer's patients, effects do not last after discontinuation of ginseng.

The second trial included 61 Alzheimer's patients; high dose *Panax ginseng* treatment (9.0 g/day) showed significant cognitive improvement (ADAS and CDR) after 12 weeks when compared with those in the control group [18]. The ginseng treatment was also associated with improvement from baseline MMSE when compared with the control (1.42 vs. -0.48), but this improvement was not statistically significant.

There has been one controlled trial in 40 moderately severe Alzheimer's patients. Patients who were in the high-dose ginseng group (4.5 g/day) showed improvements in ADAS-cog, ADAS-non-cog, and MMSE scores as early as after 12 weeks, and also at 24-weeks [19]. The results are not conclusive, however, because the control group had higher cognitive scores (ADAS-Cog, non-cog, and MMSE) at baseline. ADAS-Cog in the treatment group ranged from 40-48, while ADAS-Cog in the control group was 30.2.

The longest controlled trial in 61 Alzheimer's patients lasted 2 years. In the low-dose group (4.5 g/day of total powder capsule using a 6-year-old *Panax ginseng* root), the baseline MMSE was  $22.0 \pm 4.0$  and improved to  $25.7 \pm 3.0$  at 48 weeks, and  $23.7 \pm 4.8$  at 96 weeks [20]. In the high-dose group (9.0 g/day), the baseline MMSE was  $21.4 \pm 6.6$ , improved to  $22.0 \pm 5.7$  at 48 weeks, and  $24.0 \pm 3.7$  at 96 weeks, showing slight improvement. There was no tendency to decline. ADAS-cog showed similar findings of improvement from  $19.7 \pm 6.8$  (baseline) to  $9.5 \pm 6.3$  (96 weeks) in the low-dose group, and from  $23.0 \pm 8.7$  (baseline) to  $12.8 \pm 6.8$  (96 weeks) in the high dose group. In this study, maximum improvement was observed around 24 weeks, then sustained for 2 years.

*Mechanisms of action for neuroprotection identified from laboratory and clinical research:*

An EEG study in healthy young volunteers reported that a single ingestion of *Panax ginseng* (200 mg, G115) led to a significant shortening of the latency of the P300 component of the evoked potential [21], suggesting that *Panax ginseng* can directly modulate brain electrical activity, and that these effects were more pronounced than those following *Ginkgo biloba*.

Numerous animal studies have shown that *Panax ginseng* (50-100 mg/kg extract or 250-1000 mg/kg crude) or ginsenoside (20 mg/kg) treatments ameliorate cognitive decline associated with diabetes [22], vascular dementia [23], and advanced glycation end (AGE) product [24]. These treatments improved cognitive functions by inhibiting oxidative/nitrosative damage [22], increasing antioxidant enzymes (GSH, SOD) [25], increasing acetylcholine levels (ChAT, VAcHT expression) [25], decreasing inflammation (IL-1 $\beta$ , IL-6, TNF- $\alpha$ , NF $\kappa$ B) [22; 24], and decreasing apoptosis (upregulating Bcl-2, downregulating Bax) [23].

Ginsenosides, which are triterpene saponins, are considered the main active compounds that contribute to the purported cognitive effects of ginseng [1]. The half-life of many ginsenosides is short (range, 0.2-18 h) and bioavailability is low [1]. However, many ginsenosides have been reported to cross the blood-brain barrier, including Ginsenoside Rg1 [26; 27]. More details can be found in CognitiveVitality Reports for Ginsenoside Rg1 and Rg3.

APOE4 interactions: Unknown.

**Aging and related health concerns:** Ginseng intake is associated with lower risks for mortality and cancers; also, some benefits seen in Asian people with ischemic heart disease, diabetes, hypertension, hypercholesteremia, and fatigue.

*Types of evidence:*

- 8 meta-analyses or systematic reviews
- 2 randomized controlled clinical trials
- 3 observational studies
- Numerous laboratory studies

**Lifespan:** POTENTIAL BENEFIT. An observational study of 6,282 Korean people over the age of 55 reported that ginseng intake was significantly associated with decreased all-cause mortality in both men (HR 0.81; 95% CI, 0.74–0.89) and women (HR 0.89; 95% CI, 0.81–0.97) [28]. In this Korean cohort, 1,848 men and 1,832 women were infrequent or frequent ginseng users. After adjusting for age, education, occupation, drinking, smoking, self-reported chronic disease, body mass index, and blood pressure, all-cause mortality for male ginseng users remained significantly lower than that for male nonusers (HR = 0.90; 95% CI, 0.81-0.99). However, this association no longer remained significant in women (HR = 1.03; 95% CI, 0.94-1.13). Cancer-specific mortality was lower in female ginseng users than female nonusers



after adjustment for covariates (HR = 0.80; 95% CI, 0.60-1.08). Compared to nonusers, the HR for cancer-specific mortality in women was 0.84 in infrequent users (95% CI, 0.62-1.15) and 0.61 in frequent users (95% CI, 0.32-1.14), though these findings were not statistically significant ( $p=0.09$ ). Ginseng intake was not associated with cancer-specific mortality in men (HR = 0.95; 95% CI, 0.76-1.20). Mortality caused by cardiovascular diseases was not related to ginseng intake in men or women.

There is also preclinical evidence suggesting lifespan extension with ginseng. A study in *C. elegans* found that *Panax notoginseng* polysaccharides (albeit not from *Panax ginseng*) from the main root prolonged mean lifespan of wild type worms by 21% [29]. The authors attributed this lifespan extension to the elevation of antioxidant enzyme activities (e.g., SOD and catalase) and the reduction in oxidative stress (e.g., lipid peroxidation and malondialdehyde levels). They did not explore which bioactive compounds were responsible for this life-extending effects.

In a study in fruit flies, *Panax ginseng* (Korean red ginseng tonic) extended lifespan, increased resistance to starvation stress, and prevented weight gain [30]. The mean and median lifespans for flies reared on unsupplemented diet were 31.8 days and 33 days, respectively. For the flies given 1.2  $\mu\text{g/ml}$  ginseng supplementation, the mean and median lifespans were 36.4 days and 38 days, respectively. For the flies given 12  $\mu\text{g/ml}$  ginseng (highest dose tested), the mean and median lifespans were 36.1 days and 35 days, respectively. The highest ginseng dose (12  $\mu\text{g/ml}$ ) also significantly blocked weight gain while no effects were seen with the 2 lower doses (0.12 and 1.2  $\mu\text{g/ml}$ ).

In contrast to these findings, an old 1979 study in mice reported that ginseng treatment for 44 weeks (started at 8 weeks) did not significantly alter mean, median, or maximum lifespans [31]. The dose they used was 8 mg extract/kg/day, corresponding to 40 mg of whole root/kg/day, which the authors noted was roughly comparable to the recommended dose for humans.

**Diabetes:** BENEFIT. A meta-analysis of 8 randomized controlled trials in type 2 diabetes patients (total  $n=195$ ) reported that ginseng supplementation improved fasting glucose, postprandial insulin, and HOMA-IR levels, though no differences in postprandial glucose or fasting insulin were observed [32]. Types of ginseng and doses used in these studies varied; *Panax ginseng* was used at 3-5 g/day, American ginseng was used at 3 g/day, fermented red ginseng was used at 2.7 g/day, and hydrolyzed ginseng extract was used at 0.96 g/day.



An older 2014 meta-analysis of 16 randomized controlled trials testing ginseng in people with and without diabetes reported similar findings [33]. Ginseng modestly (statistically significantly) improved fasting blood glucose (mean difference= -0.31 mmol/L; 95% CI,-0.59 to -0.03).

Two other double-blind randomized controlled trials in young healthy adults also reported that an acute treatment with *Panax ginseng* (G115; 200 or 400 mg) significantly lowers fasting blood glucose levels [12; 34].

**Obesity:** BENEFIT IN ANIMAL MODELS. A meta-analysis of 16 preclinical studies reported that treatment with *Panax ginseng* significantly reduced body weight than the control group (standardized mean difference, -1.50; 95% CI, -1.90 to -1.11) [35].

**Hypertension:** MIXED, POSSIBLY A SMALL BENEFIT. Several meta-analyses have examined the effects of ginseng on hypertension and blood pressure. A 2017 meta-analysis that included 9 double-blind randomized controlled trials in patients with pre-hypertension or hypertension reported that Korean red ginseng (*Panax ginseng*) treatment reduced blood pressure [36]. In 2 trials testing acute effects of *Panax ginseng*, reductions were seen in systolic blood pressure (mean difference, -6.52 mm Hg) and diastolic blood pressure (mean difference, -5.21 mm Hg). Two other trials failed to show changes in systolic or diastolic blood pressure with North American ginseng. Five RCTs assessed the long-term effects of ginseng, of which 2 studies showed positive effects of *Panax ginseng* on reducing systolic (mean difference, -2.92 mm Hg) and diastolic blood pressure (mean difference, -3.19 mm Hg) compared with placebo.

A 2016 meta-analysis of 17 randomized controlled trials including 1,381 subjects reported no significant effect of ginseng on systolic, diastolic, or mean arterial pressure, though in a stratified analysis, systolic blood pressure appeared to improve non-significantly in people with diabetes, metabolic syndrome, and obesity (mean difference, -2.76 mm Hg) [37].

**Cholesterol:** BENEFIT. A meta-analysis of 8 randomized controlled trials in type 2 diabetes patients reported that ginseng supplementation (varied; *Panax ginseng* 3-5 g/day, American ginseng 3 g/day, fermented red ginseng, hydrolyzed ginseng extract, etc.) lowered levels of triglycerides, and total and LDL cholesterol, though no differences were seen in HDL levels [32].



A meta-analysis of 16 preclinical animal studies reported that treatment with *Panax ginseng* significantly increased serum HDL level and lowered serum LDL, triglyceride, and total cholesterol levels compared to the control group [35].

**Ischemic heart disease:** BENEFIT. Ginseng-based medicines and nitrates are commonly used in treating ischemic heart disease (angina pectoris) in China. In a meta-analysis of 18 randomized controlled trials including 1,549 patients with ischemic heart disease, ginseng-based medicines showed greater improvement in symptoms and ECG compared to nitrates [38]. Overall odds ratios (ginseng over nitrates) were 3.00 (95% CI, 2.27-3.96) in symptom improvement (n=18 RCTs) and 1.61 (95% CI, 1.20-2.15) in ECG improvement (n=10 RCTs). These results suggest that ginseng is more effective than nitrates for treating angina pectoris. However, further randomized controlled trials of higher quality, larger sample size, and longer duration/follow-up are required to verify these results.

**Breast Cancer:** BENEFIT. In a cohort study of 6,282 middle-aged Korean people, cancer-specific mortality was lower in female ginseng users than female nonusers after adjustment of relevant covariates (HR = 0.80; 95% CI, 0.60-1.08) [28]. Compared to nonusers, the HR for cancer-specific mortality in women was 0.84 in infrequent ginseng users (95% CI, 0.62-1.15) and 0.61 in frequent ginseng users (95% CI, 0.32-1.14), though this effect did not reach statistical significance ( $p=0.09$ ).

In a cohort of 1,455 breast cancer patients from the Shanghai Breast Cancer Study, compared with patients who never used ginseng, regular users had a significantly reduced risk of mortality [39]. Adjusted HRs associated with ginseng use were 0.71 (95% CI, 0.52-0.98) for total mortality and 0.70 (95% CI, 0.53-0.93) for disease-specific mortality or recurrence. Ginseng use after cancer diagnosis, particularly current use, was positively associated with QOL scores, with the strongest effect in the psychological and social well-being domains. Additionally, QOL improved as cumulative ginseng use increased. This study suggests that regular use of ginseng at a dose of 1.3 g per day may improve both overall and disease-free survival and enhance the QOL of Chinese breast cancer survivors.

Numerous preclinical studies have reported that ginseng may inhibit the growth of both estrogen-sensitive and estrogen-insensitive breast cancer cells, induce apoptosis of breast cancer cells, and exert synergistic benefits with chemotherapeutic agents [39].

**Colorectal Cancer:** BENEFIT. In a meta-analysis of 8 observational studies and 1 randomized clinical trial (a total of 7,436 cancer cases out of 334,544 subjects), ginseng intake was associated with reduced risk for colorectal cancer (summary RR=0.77) [40].



Several *in vitro* and *in vivo* studies have shown that ginseng not only reduces the incidence of colorectal cancer, but also improves patients' status by enhancing the effects of chemotherapy drugs [41]. Mechanisms are not entirely clear, but preclinical studies have shown antioxidant and anti-inflammatory effects as well as promotion/induction of apoptosis in cancer cells. For example, ginseng alters mitochondrial membrane permeability, increases cytochrome C release into the cytosol, and activates caspase 3 and 9 to promote cancer cell death. Ginsenosides have also been shown to increase death receptor DR4 expression and activate caspase 3 and 8 [42]. Ginsenosides Rh2, Rg3, and Rk1 inhibit the NF- $\kappa$ B pathway and cell proliferation while inducing apoptosis in cancer cells. Of the bioactive compounds in ginseng, ginsenosides Rg3 and Rh2 appear to produce the most anticancer effects; however, there is a need for further studies to confirm these findings.

In a mouse model of colorectal cancer, Ginsenoside Rg3 (10 mg/kg/day, intragastric) significantly enhanced the efficacy of radiotherapy by improving the quality of life of mice and shrinking tumor volumes [43]. Rg3 enhanced the antitumor effects of radiotherapy by suppressing NF- $\kappa$ B and NF- $\kappa$ B-regulated gene products (cyclin D1, survivin, COX-2, and VEGF), leading to inhibition of tumors and extension of lifespan in mice with colorectal cancer. The Rg3+radiation combination treatment was also effective in suppressing angiogenesis, as indicated by lower CD31+ microvessel density compared with controls.

**Other Cancers:** BENEFIT. In a meta-analysis of 8 observational studies and 1 randomized clinical trial (a total of 7,436 cancer cases out of 334,544 subjects), ginseng intake was associated with reduced risk for lung cancer (summary RR=0.77), liver cancer (summary RR=0.81), and gastric cancer (RR=0.83) [40]. Because there was only one study for each, meta-analysis data was not available for breast cancer (RR=0.71), hematologic malignancies (RR=0.75), and prostate cancer (RR=0.88).

In a cohort study of 42 patients with stage III gastric cancer, 5-year disease free survival and overall survival rate was significantly higher in patients taking red ginseng powder during postoperative chemotherapy versus control (68.2% versus 33.3%, 76.4% versus 38.5%, respectively,  $p < 0.05$ ) [44]. Red ginseng powder may have some immunomodulatory properties associated with CD3 and CD4 activity in patients with advanced gastric cancer during postoperative chemotherapy. More specifically, flow cytometric analyses for peripheral T-lymphocyte subsets showed that the red ginseng powder restored CD4 levels to the initial preoperative values during postoperative chemotherapy. Depression of CD3 during postoperative chemotherapy was also inhibited by the red ginseng powder ingestion.



**Fatigue:** BENEFIT. A meta-analysis of 12 randomized controlled trials including 630 subjects reported that there was a statistically significant effect of ginseng supplements (9 *Panax ginseng*, 2 *Panax quinquefolius*, and 1 *Panax notoginseng*) on fatigue reduction (standardized mean difference = 0.34; 95% CI, 0.16 to 0.52). However, ginseng supplements were not associated with physical performance enhancement based on 8 trials (SMD = -0.01; 95% CI, -0.29 to 0.27).

**Safety:** Numerous meta-analyses have reported that ginseng is generally safe when taken alone; however, ginseng interacts with several medications.

*Types of evidence:*

- 4 meta-analyses or systematic reviews
- 4 clinical trials
- Several laboratory studies

**Clinical data:** A 2010 Cochrane meta-analysis of 9 double-blind randomized controlled trials using ginseng extract reported no serious adverse events [8]. A newer 2013 systematic review of 30 randomized controlled trials testing any type of ginseng (Korean or American) reported that ginseng is generally safe and no serious adverse effects have been reported [45]. Two trials reported gastric upset and one reported constipation in the intervention group. The other trials reported various adverse effects that were not related to the intervention.

A 2002 systematic review of randomized controlled trials that included data on adverse effects and drugs interactions with *Panax ginseng* reported that the incidence of adverse events with ginseng monopreparations is comparable to that with placebo [46]. The most commonly experienced adverse events were headache, sleep, and gastrointestinal issues. The possibility of more serious adverse events is indicated in isolated case reports and data from spontaneous reports; however, causality is often difficult to determine from the evidence provided. In contrast, combination products containing ginseng as one of several constituents have been associated with serious adverse events and even fatalities. Interpretation of these cases is difficult as ingredients other than *Panax ginseng* may have caused the problems. Collectively, these data suggest that *Panax ginseng* monopreparations are rarely associated with adverse events.

In a meta-analysis of 18 randomized controlled trials in patients with ischemic heart disease, 4 studies reported adverse events, 2 studies reported no adverse events, and 1 study reported 3 subjects

experienced a headache in the control group but no adverse events were seen in the ginseng group [38]. Another study reported that 8 participants suffered from headache in the control group and one participant got thirsty.

In a small trial in Alzheimer's patients, 2 years of Korean red ginseng (*Panax ginseng*) treatment (4.5 or 9.0 g/day) was not associated with a significant difference in adverse events compared to control groups [20]. Five patients in the low-dose ginseng group, 6 patients in the high-dose ginseng group, and 12 patients in the control group reported adverse effects and withdrew from the study during the first 24 weeks. Participants reported mild symptoms of heat sensation, nausea, diarrhea, and headache, and all subjects who reported adverse events withdrew from the study. However, the adverse events experienced by these patients were generally tolerable and subsided without specific treatment.

In a small trial in moderately severe Alzheimer's patients, there was no significant difference in adverse events between the 3 ginseng treatment groups and the control. At the 24-week follow-up, 4 patients in each group complained of adverse events, including urticaria, headache, palpitation, nausea, and irritability [19]. All patients who reported adverse events withdrew from the study. However, the adverse events experienced by these patients were usually tolerable and subsided without treatment.

**Drug interactions:** Ginseng affects blood sugar levels, and therefore may interact with anti-diabetics ([WebMD.com](http://WebMD.com)). Ginseng also interacts with warfarin, aspirin, medications for depression, and immunosuppressants (e.g., azathioprine, basiliximab, cyclosporine, tacrolimus, sirolimus, prednisone, and other corticosteroids) ([Drugs.com](http://Drugs.com)). Ginseng may intensify the effects of caffeine and other stimulants, leading to a rapid heartbeat, sweating, or insomnia. Additional interactions with ginseng have been reported with phenelzine and alcohol [46]. A list of 124 drugs that moderately interact with ginseng can be found at [Drugs.com](http://Drugs.com).

A rodent pharmacokinetic study reported that *Panax ginseng* (30-100 mg/kg) significantly increased expression of cytochrome p450 CYP3A11 protein in the liver and of organic anion transporter OAT1 in the kidney, and OAT1, OAT3, and multiple drug resistance receptor MDR1 in the liver [47]. Although there were no significant changes in the metabolism of midazolam, ginseng significantly decreased the systemic exposure of fexofenadine in a dose-dependent manner. Only midazolam and fexofenadine were used as probe drugs; interactions with other drugs were not tested.

**Sources:** *Panax ginseng* and other ginsengs are available OTC as whole root, liquid extract, capsule, and powder forms. All ginseng produced in South Korea is *Panax ginseng*, while ginseng produced in China



includes *Panax ginseng* and *Panax notoginseng*. Ginseng produced in the US and Canada is mostly American ginseng (*Panax quinquefolius*). *Panax ginseng* is the most widely studied in clinical studies and contains different types and proportions of ginsenosides compared to other species of ginseng.

Ginseng is a slow-growing perennial herb and the roots take 4-6 years to reach maturity. *Panax ginseng* often comes in either white or red ginseng. White ginseng is fresh ginseng that has been air-dried without being heated. Red ginseng is first steamed, then dried, and has a reddish color. Red ginseng has strong stimulating and restoring effects and is often used in short-term settings for restoring vitality and energy [39]. White ginseng, on the other hand, has a milder effect and is often used for a longer time to promote health and enhance disease resistance.

**Doses:** Doses vary across studies and formulations. Ginseng is often taken in doses of 200-400 mg/day ([Examine.com](http://Examine.com)). It can also be consumed as soup (e.g., Samgye-tang, which is ginseng chicken soup), tea (Insam-cha, or ginseng tea), liquor (Insam-ju, or ginseng liquor), or in energy drinks.

**Research underway:** There are [36 ongoing clinical trials](#) testing the effects of ginseng, though statuses of many of them are unknown (no updates in the last few years). A new randomized controlled trial (posted on July 6, 2018) will be investigating the acute and chronic effects of an American ginseng root extract on cognition and mood in young adults (age 18-30) ([NCT03579095](https://clinicaltrials.gov/ct2/show/study/NCT03579095)). They will be testing a supplement called Cereboost (200 mg/day) for 14 days versus placebo. This study is estimated to be completed in August 2018.

A retrospective study in China is investigating the effectiveness of Chinese herbal medicine in Alzheimer's disease ([NCT03221894](https://clinicaltrials.gov/ct2/show/study/NCT03221894)). The herbal supplement GRAPE granules consist of ginseng, *Rehmannia glutinosa*, *Acorus tatarinowii*, *Curcuma aromatica*, and others. This study was scheduled to be completed in September 2017, but no results have been posted.

Other clinical trials are testing the effects of ginseng on management of hypertension ([NCT01578837](https://clinicaltrials.gov/ct2/show/study/NCT01578837)), atherosclerosis ([NCT02796664](https://clinicaltrials.gov/ct2/show/study/NCT02796664)), and cancer-related fatigue ([NCT03407716](https://clinicaltrials.gov/ct2/show/study/NCT03407716)).

#### Search terms:

Pubmed, Google: ginseng

- + meta-analysis, + clinical trial, + cognitive, + memory, + blood-brain barrier, + APOE, + lifespan, + mortality, + cancer



#### Websites visited for ginseng or ginsenoside:

- Clinicaltrials.gov
- [Examine.com](#)
- [Treato.com](#)
- [DrugAge \(4\)](#)
- Geroprotectors (0)
- [Drugs.com](#)
- [WebMD.com](#)
- [PubChem](#)
- [DrugBank.ca](#)
- [Labdoor.com](#)
- [ConsumerLab.com](#)
- Cafepharma.com (0)

#### References:

1. Smith I, Williamson EM, Putnam S *et al.* (2014) Effects and mechanisms of ginseng and ginsenosides on cognition. *Nutr Rev* 72, 319-333. <https://www.ncbi.nlm.nih.gov/pubmed/24666107>
2. Yang Y, Ren C, Zhang Y *et al.* (2017) Ginseng: An Nonnegligible Natural Remedy for Healthy Aging. *Aging Dis* 8, 708-720. <https://www.ncbi.nlm.nih.gov/pubmed/29344412>
3. LaSala GS, McKeever RG, Patel U *et al.* (2015) Effect of single-dose Ginkgo biloba and Panax ginseng on driving performance. *Clin Toxicol (Phila)* 53, 108-112. <https://www.ncbi.nlm.nih.gov/pubmed/25597699>
4. Ong Lai Teik D, Lee XS, Lim CJ *et al.* (2016) Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity: A Randomised Trial. *PLoS One* 11, e0150447. <https://www.ncbi.nlm.nih.gov/pubmed/26938637>
5. Persson J, Bringlov E, Nilsson LG *et al.* (2004) The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy volunteers. *Psychopharmacology (Berl)* 172, 430-434. <https://www.ncbi.nlm.nih.gov/pubmed/14647971>
6. Reay JL, Scholey AB, Kennedy DO (2010) Panax ginseng (G115) improves aspects of working memory performance and subjective ratings of calmness in healthy young adults. *Hum Psychopharmacol* 25, 462-471. <https://www.ncbi.nlm.nih.gov/pubmed/20737519>
7. Yeo HB, Yoon HK, Lee HJ *et al.* (2012) Effects of Korean Red Ginseng on Cognitive and Motor Function: A Double-blind, Randomized, Placebo-controlled Trial. *J Ginseng Res* 36, 190-197. <https://www.ncbi.nlm.nih.gov/pubmed/23717119>
8. Geng J, Dong J, Ni H *et al.* (2010) Ginseng for cognition. *Cochrane Database Syst Rev*, CD007769. <https://www.ncbi.nlm.nih.gov/pubmed/21154383>



9. D'Angelo L, Grimaldi R, Caravaggi M *et al.* (1986) A double-blind, placebo-controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers. *J Ethnopharmacol* 16, 15-22. <https://www.ncbi.nlm.nih.gov/pubmed/3528672>
10. Sünram-Lea SI, Birchall RJ, Wesnes KA *et al.* (2005) The effect of acute administration of 400mg of Panax ginseng on cognitive performance and mood in healthy young volunteers. *Current Topics in Nutraceutical Research* 3, 65-74
11. Sørensen H, Sonne J (1996) A double-masked study of the effects of ginseng on cognitive functions. *Current Therapeutic Research* 57, 959-968
12. Reay JL, Kennedy DO, Scholey AB (2005) Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity. *J Psychopharmacol* 19, 357-365. <https://www.ncbi.nlm.nih.gov/pubmed/15982990>
13. Neale C, Camfield D, Reay J *et al.* (2013) Cognitive effects of two nutraceuticals Ginseng and Bacopa benchmarked against modafinil: a review and comparison of effect sizes. *Br J Clin Pharmacol* 75, 728-737. <https://www.ncbi.nlm.nih.gov/pubmed/23043278>
14. Lho SK, Kim TH, Kwak KP *et al.* (2018) Effects of lifetime cumulative ginseng intake on cognitive function in late life. *Alzheimers Res Ther* 10, 50. <https://www.ncbi.nlm.nih.gov/pubmed/29793529>
15. Wang Y, Yang G, Gong J *et al.* (2016) Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Curr Top Med Chem* 16, 529-536. <https://www.ncbi.nlm.nih.gov/pubmed/26268331>
16. Lee MS, Yang EJ, Kim JI *et al.* (2009) Ginseng for cognitive function in Alzheimer's disease: a systematic review. *J Alzheimers Dis* 18, 339-344. <https://www.ncbi.nlm.nih.gov/pubmed/19584437>
17. Lee ST, Chu K, Sim JY *et al.* (2008) Panax ginseng enhances cognitive performance in Alzheimer disease. *Alzheimer Dis Assoc Disord* 22, 222-226. <https://www.ncbi.nlm.nih.gov/pubmed/18580589>
18. Heo JH, Lee ST, Chu K *et al.* (2008) An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. *Eur J Neurol* 15, 865-868. <https://www.ncbi.nlm.nih.gov/pubmed/18684311>
19. Heo JH, Lee ST, Chu K *et al.* (2012) Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's disease. *Nutr Neurosci* 15, 278-282. <https://www.ncbi.nlm.nih.gov/pubmed/22780999>
20. Heo JH, Lee ST, Oh MJ *et al.* (2011) Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with korean red ginseng. *J Ginseng Res* 35, 457-461. <https://www.ncbi.nlm.nih.gov/pubmed/23717092>
21. Kennedy DO, Scholey AB, Drewery L *et al.* (2003) Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. *Pharmacol Biochem Behav* 75, 701-709. <https://www.ncbi.nlm.nih.gov/pubmed/12895688>
22. Tian Z, Ren N, Wang J *et al.* (2018) Ginsenoside Ameliorates Cognitive Dysfunction in Type 2 Diabetic Goto-Kakizaki Rats. *Med Sci Monit* 24, 3922-3928. <https://www.ncbi.nlm.nih.gov/pubmed/29886506>
23. Zhu JD, Wang JJ, Zhang XH *et al.* (2018) Panax ginseng extract attenuates neuronal injury and cognitive deficits in rats with vascular dementia induced by chronic cerebral hypoperfusion. *Neural Regen Res* 13, 664-672. <https://www.ncbi.nlm.nih.gov/pubmed/29722318>

24. Tan X, Gu J, Zhao B *et al.* (2015) Ginseng improves cognitive deficit via the RAGE/NF-kappaB pathway in advanced glycation end product-induced rats. *J Ginseng Res* 39, 116-124. <https://www.ncbi.nlm.nih.gov/pubmed/26045684>
25. Lee MR, Ma JY, Sung CK (2017) Chronic dietary ginseng extract administration ameliorates antioxidant and cholinergic systems in the brains of aged mice. *J Ginseng Res* 41, 615-619. <https://www.ncbi.nlm.nih.gov/pubmed/29021712>
26. Shen J, Zhao Z, Shang W *et al.* (2017) Ginsenoside Rg1 nanoparticle penetrating the blood-brain barrier to improve the cerebral function of diabetic rats complicated with cerebral infarction. *Int J Nanomedicine* 12, 6477-6486. <https://www.ncbi.nlm.nih.gov/pubmed/28919749>
27. Xue W, Liu Y, Qi WY *et al.* (2016) Pharmacokinetics of ginsenoside Rg1 in rat medial prefrontal cortex, hippocampus, and lateral ventricle after subcutaneous administration. *J Asian Nat Prod Res* 18, 587-595. <https://www.ncbi.nlm.nih.gov/pubmed/27324597>
28. Yi SW, Sull JW, Hong JS *et al.* (2009) Association between ginseng intake and mortality: Kangwha cohort study. *J Altern Complement Med* 15, 921-928. <https://www.ncbi.nlm.nih.gov/pubmed/19678784>
29. Feng S, Cheng H, Xu Z *et al.* (2015) Thermal stress resistance and aging effects of Panax notoginseng polysaccharides on *Caenorhabditis elegans*. *Int J Biol Macromol* 81, 188-194. <https://www.ncbi.nlm.nih.gov/pubmed/26234580>
30. Kim MS (2013) Korean Red Ginseng Tonic Extends Lifespan in *D. melanogaster*. *Biomol Ther (Seoul)* 21, 241-245. <https://www.ncbi.nlm.nih.gov/pubmed/24265871>
31. Bittles AH, Fulder SJ, Grant EC *et al.* (1979) The effect of ginseng on lifespan and stress responses in mice. *Gerontology* 25, 125-131. <https://www.ncbi.nlm.nih.gov/pubmed/571386>
32. Gui QF, Xu ZR, Xu KY *et al.* (2016) The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. *Medicine (Baltimore)* 95, e2584. <https://www.ncbi.nlm.nih.gov/pubmed/26871778>
33. Shishtar E, Sievenpiper JL, Djedovic V *et al.* (2014) The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. *PLoS One* 9, e107391. <https://www.ncbi.nlm.nih.gov/pubmed/25265315>
34. Reay JL, Kennedy DO, Scholey AB (2006) The glycaemic effects of single doses of Panax ginseng in young healthy volunteers. *Br J Nutr* 96, 639-642. <https://www.ncbi.nlm.nih.gov/pubmed/17010221>
35. Park HS, Cho JH, Kim KW *et al.* (2018) Effects of Panax ginseng on Obesity in Animal Models: A Systematic Review and Meta-Analysis. *Evid Based Complement Alternat Med* 2018, 2719794. <https://www.ncbi.nlm.nih.gov/pubmed/29861768>
36. Lee HW, Lim HJ, Jun JH *et al.* (2017) Ginseng for Treating Hypertension: A Systematic Review and Meta-Analysis of Double Blind, Randomized, Placebo-Controlled Trials. *Curr Vasc Pharmacol* 15, 549-556. <https://www.ncbi.nlm.nih.gov/pubmed/28707603>
37. Komishon AM, Shishtar E, Ha V *et al.* (2016) The effect of ginseng (genus Panax) on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. *J Hum Hypertens* 30, 619-626. <https://www.ncbi.nlm.nih.gov/pubmed/27074879>
38. Jia Y, Zhang S, Huang F *et al.* (2012) Could ginseng-based medicines be better than nitrates in treating ischemic heart disease? A systematic review and meta-analysis of randomized controlled trials. *Complement Ther Med* 20, 155-166. <https://www.ncbi.nlm.nih.gov/pubmed/22500665>



39. Cui Y, Shu XO, Gao YT *et al.* (2006) Association of ginseng use with survival and quality of life among breast cancer patients. *Am J Epidemiol* 163, 645-653. <https://www.ncbi.nlm.nih.gov/pubmed/16484447>
40. Jin X, Che DB, Zhang ZH *et al.* (2016) Ginseng consumption and risk of cancer: A meta-analysis. *J Ginseng Res* 40, 269-277. <https://www.ncbi.nlm.nih.gov/pubmed/27616903>
41. Vayghan HJ, Ghadimi SS, Nourazarian AR (2014) Preventive and therapeutic roles of ginseng - focus on colon cancer. *Asian Pac J Cancer Prev* 15, 585-588. <https://www.ncbi.nlm.nih.gov/pubmed/24568461>
42. Qi LW, Wang CZ, Yuan CS (2010) American ginseng: potential structure-function relationship in cancer chemoprevention. *Biochem Pharmacol* 80, 947-954. <https://www.ncbi.nlm.nih.gov/pubmed/20599804>
43. Liu T, Duo L, Duan P (2018) Ginsenoside Rg3 Sensitizes Colorectal Cancer to Radiotherapy through Downregulation of Proliferative and Angiogenic Biomarkers. *Evid Based Complement Alternat Med* 2018, 1580427. <https://www.ncbi.nlm.nih.gov/pubmed/29743919>
44. Suh SO, Kroh M, Kim NR *et al.* (2002) Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. *Am J Chin Med* 30, 483-494. <https://www.ncbi.nlm.nih.gov/pubmed/12568276>
45. Choi J, Kim TH, Choi TY *et al.* (2013) Ginseng for health care: a systematic review of randomized controlled trials in Korean literature. *PLoS One* 8, e59978. <https://www.ncbi.nlm.nih.gov/pubmed/23560064>
46. Coon JT, Ernst E (2002) Panax ginseng: a systematic review of adverse effects and drug interactions. *Drug Saf* 25, 323-344. <https://www.ncbi.nlm.nih.gov/pubmed/12020172>
47. Kim SJ, Choi S, Kim M *et al.* (2018) Effect of Korean Red Ginseng extracts on drug-drug interactions. *J Ginseng Res* 42, 370-378. <https://www.ncbi.nlm.nih.gov/pubmed/29989018>

**Disclaimer:** Cognitive Vitality Reports® do not provide, and should not be used for, medical advice, diagnosis, or treatment. You should consult with your healthcare providers when making decisions regarding your health. Your use of these reports constitutes your agreement to the [Terms & Conditions](#).

If you have suggestions for drugs, drugs-in-development, supplements, nutraceuticals, or food/drink with neuroprotective properties that warrant in-depth reviews by ADDF's Aging and Alzheimer's Prevention Program, please contact [INFO@alzdiscovery.org](mailto:INFO@alzdiscovery.org). To view our official ratings, visit [Cognitive Vitality's Rating page](#).